We also examined the effect of GZ17-6.02 on recently identified glioblastoma super-enhancer genes WSCD1, EVOL2, and KLHDC8A as well as the enzyme FADS2, which mediates ELOVL2 signaling [8]. This evidence concerns the gene WSCD1 and glioblastoma.